🚀 Tilray (TLRY) Skyrockets 20%: Jefferies Upgrade & Cannabis Policy Hype Fuel Epic Rally

Tilray shares just ripped through the charts—Jefferies analysts slapped on a bullish upgrade while cannabis policy optimism sent traders into a frenzy.

### The Upgrade Catalyst

Jefferies didn’t hold back—Tilray’s potential looks stronger than ever. Fresh analyst confidence merged with regulatory tailwinds lit a fire under TLRY’s momentum.

### Policy Momentum Builds

Speculation around loosened cannabis laws is gaining steam. Traders are betting big—this isn’t just a pump; it’s a policy play with real legs.

### A Penny Stock No More?

Tilray’s 20% surge screams momentum—but let’s be real, in the world of hype-driven rallies, even analysts sometimes chase the trend. Whether it holds or not? That’s the real trade.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Analyst’s Take on Tilray

The 4-star analyst said Trump’s effort to reclassify cannabis from Schedule I to Schedule III WOULD mark a “meaningful shift in federal stance” that improves access, eases taxes, and allows more research. “Tilray is the biggest potential beneficiary,” he added, noting strong public support and ongoing reform discussions in Congress could provide further momentum. While reclassification is not full legalization, he emphasized it would still be a transformative catalyst, particularly for Canadian producers like Tilray.

The bullish call also drove heavy trading in Tilray stock, with more than 150 million shares changing hands on Monday, almost triple the 50-day average. It marked Tilray’s third straight day of gains as investors returned to cannabis stocks amid policy optimism.

Policy Shift Could Boost Cannabis

Trump recently said that a review of marijuana’s classification under U.S. law is underway, with a decision expected “within weeks.” The proposal would move cannabis from Schedule I, the most restrictive category, to Schedule III, which includes drugs with accepted medical use and lower abuse risk.

Investors see this as a potential turning point for cannabis companies. A Schedule III label would ease taxes, make research easier, and open the door to broader commercial use. It could also attract more institutional investors into the sector.

 Is TLRY a Good Buy?

Turning to Wall Street, analysts have a Moderate Buy consensus rating on TLRY stock based on two Buys and three Holds assigned in the past three months. Furthermore, the average Tilray stock price target of $1.03 per share implies a downside of about 30% from the current level.